Bibliografía

1. Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid, Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la Salud - I+CS; 2006. Guías de Práctica Clínica en el SNS: I+CS Nº 2006/1.

2. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14(2):223-36.

3. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, et al. Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol. 2009;8(12):1128-39.

4. Juri C, Rodriguez-Oroz M, Obeso JA. The pathophysiological basis of sensory disturbances in Parkinson’s disease. J Neurol Sci. 2010;289(1-2):60-5.

5. Biundo R, Calabrese M, Weis L, Facchini S, Ricchieri G, Gallo P, et al. Anatomical correlates of cognitive functions in early Parkinson’s disease patients. PLoS ONE. 2013;8(5):e64222.

6. Sauerbier A, Ray CK. Non-motor symptoms: the core of multi-morbid Parkinson’s disease. Br J Hosp Med (Lond). 2014;75(1):18-24.

7. Kremens D, Hauser RA, Dorsey ER. An update on Parkinson’s disease: improving patient outcomes. Am J Med. 2014;127(1):S3.

8. Hanagasi HA, Emre M. Treatment of behavioural symptoms and dementia in Parkinson’s disease. Fundam Clin Pharmacol. 2005;19(2):133-46.

9. Aminoff MJ, Christine CW, Friedman JH, Chou KL, Lyons KE, Pahwa R, et al. Management of the hospitalized patient with Parkinson’s disease: current state of the field and need for guidelines. Parkinsonism Relat Disord. 2011;17(3):139-45.

10. Peters C, Currin M, Tyson S, Rogers A, Healy S, McPhail S, et al. A randomized controlled trial of an enhanced interdisciplinary community based group program for people with Parkinson’s disease: study rationale and protocol. Neurol Int. 2012;4(1):e3.

11. Patrones de mortalidad en España, 2011 [monografía en Internet]. Madrid. Ministerio de Sanidad, Servicios Sociales e Igualdad, 2014. Consultado: 05/07/2014. Disponible en http://www.mssi.gob.es/estadEstudios/estadisticas/estadisticas/
estMinisterio/mortalidad/mortalidad.htm.

12. Ministerio de Sanidad Servicios Sociales e Igualdad. Estrategia para el Abordaje de la Cronicidad en el Sistema Nacional de Salud. Madrid: 2012.

13. National Collaborating Centre for Chronic Conditions, Comissioned by the National Institute for Health and Clinical Evidence. Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians; 2006.

14. Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological management of Parkinson’s disease: a national clinical guideline. Edinburgh: SIGN;2010.

15. Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(10):728-41.

16. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The movement disorder society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(SUPPL. 3):S2-41.

17.Reese JP, Dams J, Winter Y, Balzer-Geldsetzer M, Oertel WH, Dodel R. Pharmacoeconomic considerations of treating patients with advanced Parkinson’s disease. Expert Opin Pharmacother. 2012;13(7):939-58.

18. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, doubleblind, double-dummy study. Lancet Neurol. 2014;13(2):141-9.

19. Zoccolella S, Savarese M, Lamberti P, Manni R, Pacchetti C, Logroscino G. Sleep disorders and the natural history of Parkinson’s disease: the contribution of epidemiological studies. Sleep Med Rev. 2011;15(1):41-50.

20. Diederich NJ, McIntyre DJ. Sleep disorders in Parkinson’s disease: Many causes, few therapeutic options. J Neurol Sci. 2012;314(1-2):12-9.

21. Opara JA, Brola W, Leonardi M, Blaszczyk B. Quality of life in Parkinson’s disease. J Med Life. 2012;5(4):375-81.

22. Maass A, Reichmann H. Sleep and non-motor symptoms in Parkinson’s disease. J Neural Transm. 2013;120(4):565-9.

23. Louter M, Aarden WC, Lion J, Bloem BR, Overeem S. Recognition and diagnosis of sleep disorders in Parkinson’s disease. J Neurol. 2012;259(10):2031-40.

24. Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord. 2009;15 Suppl 4:S111-5.

25. Pirritano D, Plastino M, Fava A, Cristiano D, Gallelli L, Colica C, et al. Pathological gambling in Parkinson’s disease: An update on medical management. Curr Psychopharmacol. 2012;1(4):365-74.

26. Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68(3):400-4.

27. Raja M, Bentivoglio AR. Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson’s disease and other disorders. Curr Drug Saf. 2012;7(1):63-75.

28. Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug Saf. 2009;32(6):475-88.

29. Callesen MB, Scheel-Kruger J, Kringelbach ML, Moller A. A systematic review of impulse control disorders in Parkinson’s disease. J Parkinsons Dis. 2013;3(2):105-38.

30. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;(3):CD006504.

31. Van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE. Effects of Cholinesterase Inhibitors in Parkinson’s Disease Dementia: A Review of Clinical Data. CNS Neurosci Ther. 2011;17(5):428-41.

32. Willan AR, Goeree R, Pullenayegum EM, McBurney C, Blackhouse G. Economic evaluation of rivastigmine in patients with Parkinson’s disease dementia. PharmacoEconomics. 2006;24(1):93-106.

33. Santos-García D, Aneiros-Díaz A, Macías-Arribi M, Llaneza-González MA, Abella-Corral J, Santos-Canelles H. Síntomas sensoriales en la enfermedad de Parkinson. Rev Neurol. 2010;50(Supl.2):S65-74.

34. Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, Ory-Magne F, Slaoui T, Rascol O, et al. Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78(10):1140-2.

35. Lim SY, Farrell MJ, Gibson SJ, Helme RD, Lang AE, Evans AH. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson’s disease? Mov Disord. 2008;23(12):1689-95.

36. Dellapina E, Gerdelat-Mas A, Ory-Magne F, Pourcel L, Galitzky M, Calvas F, et al. Apomorphine effect on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2011;26(1):153-7.

37. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26 Suppl 3:S42-80.

38.Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011;17(10):724-9.

39. Perez-Lloret S, Rey MV, Pavy-Le Traon A, Rascol O. Orthostatic hypotension in Parkinson’s disease. Neurodegenerative Dis Manage. 2013;3(4):363-77.

40. Vázquez Sánchez F, Rodríguez Martínez E, Luque A. Trastornos urinarios, disfunción sexual e hipersexualidad en la enfermedad de Parkinson. Rev neurol , (Barcelona). 2010;50(supl.2):S27-31.

41. Van der Marck MA, Dicke HC, Uc EY, Kentin ZHA, Borm GF, Bloem BR, et al. Body mass index in Parkinson’s disease: A meta-analysis. Parkinsonism Relat Disord. 2012;18(3):263-7.

42. Sheard JM, Ash S, Silburn PA, Kerr GK. Prevalence of malnutrition in Parkinson’ s disease: A systematic review. Nutr Rev. 2011;69(9):520-32.

43. Aziz NA, Van der Marck MA, Pijl H, Olde Rikkert MG, Bloem BR, Roos RA. Weight loss in neurodegenerative disorders. J Neurol. 2008;255(12):1872-80.

44. Perez-Lloret S, Rey MV, Pavy-Le Traon A, Rascol O. Emerging drugs for autonomic dysfunction in Parkinson’s disease. Expert Opin Emerg Drugs. 2013;18(1):39-53.

45. Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson’s disease: A prospective double-blind trial. Mov Disord. 2012;27(2):219-26.

46. Lombardi G, Nelli F, Celso M, Mencarini M, Del Popolo G. Treating Erectile Dysfunction and Central Neurological Diseases with Oral Phosphodiesterase Type 5 Inhibitors. Review of the Literature. J Sex Med. 2012;9(4):970-85.

47. Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson’s disease treated with L-dopa. Clin Neuropharmacol. 2002;25(1):21-4.

48. Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa C. Antidepressants for depression in Parkinson’s disease: systematic review and meta-analysis. J Psychopharmacol. 2013;27(5):417-23.

49. Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: A systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 2010;10(1):49.

50. Chen JJ. Parkinson’s disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care. 2010;16 Suppl Implications: S87-93.

51. Morley D, Dummett S, Peters M, Kelly L, Hewitson P, Dawson J, et al. Factors influencing quality of life in caregivers of people with Parkinson’s disease and implications for clinical guidelines. Parkinsons Dis. 2012;2012:190901.

52. Tickle-Degnen L, Ellis T, Saint-Hilaire MH, Thomas CA, Wagenaar RC. Selfmanagement rehabilitation and health-related quality of life in Parkinson’s disease: a randomized controlled trial. Mov Disord. 2010;25(2):194-204.

53. Earhart GM, Dibble LE, Ellis T, Nieuwboer A. Rehabilitation and Parkinson’s disease 2013. Parkinsons Dis. 2013;2013:506375.

54. Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, Stowe R, et al. Physiotherapy intervention in Parkinson’s disease: systematic review and metaanalysis. BMJ. 2012;345:e5004.

55. Rosenthal LS, Dorsey ER. The benefits of exercise in Parkinson disease. JAMA Neurol. 2013;70(2):156-7.

56. King LA, Salarian A, Mancini M, Priest KC, Nutt J, Serdar A, et al. Exploring outcome measures for exercise intervention in people with Parkinson’s disease. Parkinsons Dis. 2013;2013:572134.

57. Tomlinson CL, Patel S, Meek C, Clarke CE, Stowe R, Shah L, et al. Physiotherapy versus placebo or no intervention in Parkinson’s disease. Cochrane Database Syst Rev. 2012;8:CD002817.

58. Lau RW, Teo T, Yu F, Chung RC, Pang MY. Effects of whole-body vibration on sensorimotor performance in people with Parkinson disease: a systematic review. Phys Ther. 2011;91(2):198-209.

59. Fletcher E, Goodwin VA, Richards SH, Campbell JL, Taylor RS. An exercise intervention to prevent falls in Parkinson’s: an economic evaluation. BMC Health Serv Res. 2012;12:426.

60. McGinley JL, Martin C, Huxham FE, Menz HB, Danoudis M, Murphy AT, et al. Feasibility, safety, and compliance in a randomized controlled trial of physical therapy for Parkinson’s disease. Parkinsons Dis. 2012;2012:795294.

61. Schenkman M, Hall DA, Baron AE, Schwartz RS, Mettler P, Kohrt WM. Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. Phys Ther. 2012;92(11):1395-410.

62. Shulman LM, Katzel LI, Ivey FM, Sorkin JD, Favors K, Anderson KE, et al. Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. JAMA Neurol. 2013;70(2):183-90.

63. Corcos DM, Robichaud JA, David FJ, Leurgans SE, Vaillancourt DE, Poon C, et al. A two-year randomized controlled trial of progressive resistance exercise for Parkinson’s disease. Mov Disord. 2013;28(9):1230-40.

64. Frazzitta G, Bertotti G, Riboldazzi G, Turla M, Uccellini D, Boveri N, et al. Effectiveness of intensive inpatient rehabilitation treatment on disease progression in parkinsonian patients: A randomized controlled trial with 1-year follow-up. Neurorehabil Neural Repair. 2012;26(2):144-50.

65. Murphy S, Tickle-Degnen L. The effectiveness of occupational therapy-related treatments for persons with Parkinson’s disease: a meta-analytic review. Am J Occup Ther. 2001;55(4):385-92.

66. Foster ER, Bedekar M, Tickle-Degnen L. Systematic review of the effectiveness of occupational therapy-related interventions for people with Parkinson’s disease. Am J Occup Ther. 2014;68(1):39-49.

67. Dixon L, Duncan D, Johnson P, Kirkby L, O’Connell H, Taylor H, et al. Occupational therapy for patients with Parkinson’s disease. Cochrane Database Syst Rev. 2007;(3):CD002813.

68. Rao AK. Enabling functional independence in Parkinson’s disease: update on occupational therapy intervention. Mov Disord. 2010;25(Supplement 1):S146-51.

69. Sturkenboom IH, Graff MJ, Hendriks JC, Veenhuizen Y, Munneke M, Bloem BR, et al. Efficacy of occupational therapy for patients with Parkinson’s disease: a randomised controlled trial. Lancet Neurol. 2014;13(6):557-66.

70. de Swart BJ, Willemse SC, Maassen BA, Horstink MW. Improvement of voicing in patients with Parkinson’s disease by speech therapy. Neurology. 2003;60(3):498-500.

71. Miller N. Speech, voice and language in Parkinsons disease: Changes and interventions. Neurodegenerative Dis Manage. 2012;2(3):279-89.

72. Murdoch B, Whitehill T, de LM, Jones H. Communication impairments in Parkinson’s disease. Parkinsons Dis. 2011;2011:234657.

73. Herd CP, Tomlinson CL, Deane KH, Brady MC, Smith CH, Sackley CM, et al. Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease. Cochrane Database Syst Rev. 2012;8:CD002812.

74. Herd CP, Tomlinson CL, Deane KH, Brady MC, Smith CH, Sackley CM, et al. Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease. Cochrane Database Syst Rev. 2012;8:CD002814.

75. Real Academia Española. Diccionario de la lengua española 22ª ed. Última actualización: 2014. Consultado: 30/04/2014. Disponible en: http://www.rae.es/recursos/diccionarios/drae.

76. Kalf JG, De Swart BJM, Bloem BR, Munneke M. Prevalence of oropharyngeal dysphagia in Parkinson’s disease: A meta-analysis. Parkinsonism Relat Disord. 2012;18(4):311-5.

77. Ashford J, McCabe D, Wheeler-Hegland K, Frymark T, Mullen R, Musson N, et al. Evidence-based systematic review: Oropharyngeal dysphagia behavioral treatments. Part III - Impact of dysphagia treatments on populations with neurological disorders. J Rehabil Res Dev. 2009;46(2):195-204.

78. Smith SK, Roddam H, Sheldrick H. Rehabilitation or compensation: time for a fresh perspective on speech and language therapy for dysphagia and Parkinson’s disease? Int J Lang Commun Disord. 2012;47(4):351-64.

79. Baijens LW, Speyer R. Effects of therapy for dysphagia in Parkinson’s disease: systematic review. Dysphagia. 2009;24(1):91-102.

80. Manor Y, Mootanah R, Freud D, Giladi N, Cohen JT. Video-assisted swallowing therapy for patients with Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(2):207-11.

81. Langenbahn DM, Ashman T, Cantor J, Trott C. An evidence-based review of cognitive rehabilitation in medical conditions affecting cognitive function. Arch Phys Med Rehabil. 2013;94(2):271-86.

82. Braun S, Kleynen M, Van Heel T, Kruithof N, Wade D, Beurskens A. The effects of mental practice in neurological rehabilitation; a systematic review and meta-analysis. Front Human Neurosci. 2013;(7):390.

83. Calleo J, Burrows C, Levin H, Marsh L, Lai E, York MK. Cognitive rehabilitation for executive dysfunction in Parkinson’s disease: Application and current directions. Parkinsons Dis. 2012;2012:512892.

84. Sato Y, Iwamoto J, Honda Y. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson’s disease. Parkinsonism Relat Disord. 2011;17(1):22-6.

85. Iwamoto J, Sato Y, Takeda T, Matsumoto H. Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: Review of the literature. Drugs Aging. 2012;29(3):191-203.

86. Powers JG, Gilchrest BA. What You and Your Patients Need to Know About Vitamin D. Semin Cutaneous Med Surg. 2012;31(1):2-10.

87. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65(10):1348-52.

88. Van Den Bos F, Speelman AD, Samson M, Munneke M, Bloem BR, Verhaar HJJ. Parkinson’s disease and osteoporosis. Age Ageing. 2013;42(2):156-62.

89. Lv Z, Qi H, Wang L, Fan X, Han F, Wang H, et al. Vitamin D status and Parkinson’s disease: a systematic review and meta-analysis. Neurol Sci. 2014.

90. Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1(alpha)-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;66(1):64-8.

91. Chen J, Guan Z, Wang L, Song G, Ma B, Wang Y. Meta-Analysis: Overweight, Obesity, and Parkinson’s Disease. Int J Endocrinol. 2014;2014:203930.

92. Barichella M, Savardi C, Mauri A, Marczewska A, Vairo A, Baldo C, et al. Diet with LPP for renal patients increases daily energy expenditure and improves motor function in Parkinsonian patients with motor fluctuations. Nutr Neurosci. 2007;10(3-4):129-35.

93. Cereda E, Barichella M, Pedrolli C, Pezzoli G. Low-protein and protein-redistribution diets for Parkinson’s disease patients with motor fluctuations: a systematic review. Mov Disord. 2010;25(13):2021-34.

94. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-42.

95. Alonso A, Aroca G, Catalán MJ, Crespillo MR, Chueca EP, Donate S, et al. Guía de orientación en la práctica profesional de la valoración reglamentaria de la situación de dependencia en personas con enfermedad de Parkinson. Ministerio de Sanidad, Servicios Sociales e Igualdad. Instituto de Mayores y Servicios Sociales (Imserso); 2012.

96. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Consultado: 27/03/014. Disponible en: http://www.aemps.gob.es.

97. NHS National Patient Safety Agency; Royal College of Speech Language Therapists; National Association of Care Catering; British Dietetic Association; National Nurses Nutrition Group; Hospital Caterers Association. Dysphagia Diet Food Texture Descriptors. NHS National Patient Safety Agency; 2012.

98. Pagonabarraga J, Kulisevky J, Campolongo A; Consejos para pacientes con Parkinson: El papel de la dieta en el Parkinson. Alteraciones conductuales y emocionales. Badalona: Euromedice, Ediciones Médicas, S.L.; 2012.

99. Dávila P, Rubí E, Mateo A. La situación de los enfermos afectados por la enfermedad de Parkinson, sus necesidades y sus demandas. Madrid: Catálogo General de Publicaciones Oficiales; 2008. Colección Estudios Serie Dependencia Nº 12009.